Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
Swiss pharma giant Roche and other global drugmakers are eyeing more active expansion in the former Soviet market within the next several years, according to recent statements by the companies and some regional media reports, reports The Pharma Letter’s Russia correspondent. 25 February 2020
Pharmaceutical
In early December 2019, the first cases of a new coronavirus emerged, a virus that has since come to grip the world’s media and worry regulators in every country. 24 February 2020
Pharmaceutical
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken by US biotech Tetra Therapeutics. 17 February 2020
Pharmaceutical
Newly-appointed Russian Prime Minister Mikhail Mishustin has instructed the national government to lift the existing restrictions on the procurement of foreign drugs, particularly those which are used for the treatment of cancer, genetic and some rare diseases, according to recent statements, made by the press-service of the Russian government and some local media, reports The Pharma Letter’s local correspondent. 17 February 2020
Pharmaceutical
A look at why US drugmaker Eli Lilly is willing to spend more than $1 billion on the takeover of dermatology specialist Dermira. 11 February 2020
Biotechnology
Every drug developer with ambitions to be part of the precision medicine revolution knows that improved detection rates are key to treating diseases earlier and more effectively. 11 February 2020
Pharmaceutical
The Coalition for Preparedness for Treatment, a public association in Russia which protects the interests of local patients, has sent an official request to the UK’s GlaxoSmithKline, asking the drugmaker to lower the price for its dolutegravir anti-HIV drug, which is sold under Tivikai brand name in the local market (Tivicay elsewhere), according to recent statements by representatives of the Association, reports The Pharma Letter’s local correspondent. 11 February 2020
Pharmaceutical
By Dr Nicola Davies
The US Food and Drug Administration has started 2020 under the leadership of Dr Stephen Hahn, their new Commissioner. Dr Hahn’s role was confirmed by the US Senate with a 72-18 vote on December 12, 2019.1 10 February 2020
Pharmaceutical
An Expert View on how licensors and licensees can best protect their patent from Charlotte Tillett and Astrid Arnold from Stevens & Bolton. 8 February 2020
Pharmaceutical
The Russian drugmaker R-Pharm has announced plans to increase the production of Kaletra (lopinavir plus ritonavir) - an anti-HIV drug, which reportedly can be effective against the new Chinese coronavirus, according to recent statements made by the chairman of the company, Alexei Repik, in an interview with Russian media, as well as some market sources, reports The Pharma Letter’s local correspondent. 4 February 2020
Pharmaceutical
Michael Jewell, partner and head of healthcare and life sciences at Cavendish Corporate Finance, considers
how four key trends look set to continue to shape the industry in an Expert View piece. 31 January 2020
Generics
American regulator the US Food and Drug Administration has issued warning letters to India’s top drug firms such as Dr Reddy’s, Sun Pharma, Lupin, Glenmark Pharmaceuticals, Biocon, Torrent Pharma, Aurobindo and Cadila, among others. Facing the heat, drug majors appear to be cleaning up their act, reports The Pharma Letter’s India correspondent. 29 January 2020
Biotechnology
In a Special Report, Patrick Laroche, Janssen EMEA Haematology Therapy Area Lead, looks at how haematology is leading the way in oncology innovation, how CAR-T has the potential to revolutionise treatment for multiple myeloma, and the challenges that lie ahead in this field. 28 January 2020
Biosimilars
Russian drugmaker Biocad and Swiss pharma giant Roche became the main suppliers of anticancer drugs as part of the Russian “Healthcare” national state project in 2019, according to recent statements made by some senior officials of the Russian Ministry of Health and some local media, reports The Pharma Letter’s local correspondent. 28 January 2020
Pharmaceutical
Zulf Masters, chief executive of Masters Speciality Pharma, provides an Expert View on the challenges and opportunities of bringing medicines to Latin America. 27 January 2020
Biotechnology
As biotech companies making themselves eligible to a big pharma buyout go, Imugene appears to tick a lot of the boxes – but the proof of the pudding will come with all important trial results. 24 January 2020
Pharmaceutical
While pharma and biotech shares have generally been buoyant in recent months, certain precipitous price drops could shine a light on the prospects for stockholders. 23 January 2020
Generics
The second round of China’s national generics procurement, which ended on January 17, saw 53% price cuts on average of the 32 drugs that treat diseases including cancer and type II diabetes. 22 January 2020
Pharmaceutical
Swiss pharma giant Novartis plans to increase the level of utilization of its Russian plant by almost four-fold until 2022, according to recent statements, made by representatives of the company and some St Petersburg media, reports The Pharma Letter’s local correspondent. 20 January 2020
Pharmaceutical
One deal skewed the picture in looking at the M&A activity by therapy area in the final quarter of 2019. 16 January 2020
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze